This Week in Nephrology — Sep 30, 2026

This AudioScholar briefing is generated by artificial intelligence for healthcare professionals and trainees. It is not medical advice.

Welcome to This Week in Nephrology. This week we're covering 10 notable papers spanning frailty and physical function in kidney disease, cardiovascular-kidney-metabolic pharmacotherapy, immune-mediated glomerular disease, and a pair of studies on transplant infection and rare disease therapeutics. Let's dive in.

We start with the theme that dominated the week: how the body's physical reserve shapes outcomes and decisions in chronic kidney disease. Nature Reviews Nephrology published a consensus report from Li and colleagues offering 63 statements across four domains on the management of frailty in chronic kidney disease [1]. The panel supports routine frailty screening with multi-dimensional tools, interventions targeting the modifiable contributors — resistance training in particular, adequate dietary protein, medication optimisation, and comprehensive geriatric assessment — and a frailty-informed, person-centred framework for shared decision-making about conservative kidney management versus kidney replacement therapy. They also endorse flexible delivery of kidney replacement therapy, including less intensive dialysis schedules, assisted home dialysis, and transplant eligibility assessment guided by serial frailty measurement. This is expert consensus rather than trial evidence, and the authors are explicit that whether frailty can actually be reversed by targeted intervention remains an open question. Complementing that, the Clinical Journal of the American Society of Nephrology reported findings from the Chronic Renal Insufficiency Cohort, where Nair and colleagues followed just over three thousand adults with a median of eight and a half years of follow-up, using the Short Physical Performance Battery [2]. Each one-point drop in the score, measured repeatedly over time, was associated with about a 15 percent higher risk of death and about a 10 percent higher risk of incident heart failure. Participants in the lower performance categories carried markedly higher risk, with mortality risk up to roughly tripled compared with the best-performing group. Notably, physical performance was not independently associated with progression to kidney failure — so this is a cardiovascular and survival signal, not a kidney-progression signal, and it is observational, meaning it identifies risk rather than establishing that improving performance improves outcomes.

Still within the theme of individualising dialysis, Seminars in Dialysis published a systematic review and meta-analysis from Mizrak and colleagues pooling 35 clinical studies of incremental haemodialysis against standard thrice-weekly full-dose treatment [3]. Incremental schedules showed no statistically significant advantage for all-cause mortality, hospitalisation, cardiovascular events, intradialytic hypotension, or quality of life — the outcomes were essentially non-inferior rather than superior. Where incremental dialysis did differ was in better preservation of residual kidney function and fewer vascular access complications. The authors are careful to note that the evidence base is largely observational and that larger prospective studies with longer follow-up are needed before widespread adoption, but this does sit alongside the frailty consensus in supporting less intensive schedules as a defensible option for selected patients.

Turning to cardiovascular-kidney-metabolic disease, the Clinical Journal of the American Society of Nephrology published a large comparative effectiveness analysis from Htoo and colleagues using Veterans Health Administration data from the United States [4]. They compared older adults aged 65 and above with type 2 diabetes and stage 3 to 4 chronic kidney disease starting either a GLP-1 receptor agonist or an SGLT2 inhibitor — roughly 28,000 and 78,000 initiators respectively — matched on more than a hundred covariates, with a median follow-up of only 11 months. For the primary composite of end-stage kidney disease, sustained 40 percent decline in kidney function, or death, the two drug classes performed essentially identically, driven largely by similar mortality. The secondary kidney outcomes favoured SGLT2 inhibitors, with higher risks of sustained kidney function decline and incident end-stage kidney disease among those starting a GLP-1 receptor agonist, and the absolute differences were larger at more advanced chronic kidney disease stages. Findings were consistent across body mass index, HbA1c and cardiovascular history subgroups. This is non-randomised data with short follow-up, and formulations approved for weight loss were excluded, so it informs rather than settles the sequencing question. Alongside that, Nature Reviews Nephrology carried a review from Sánchez-Bayuela and colleagues on targeting the aldosterone-mineralocorticoid receptor pathway across the cardiovascular-kidney-metabolic continuum [5]. The authors summarise the case that non-steroidal antagonists such as finerenone offer greater tissue selectivity and a more favourable safety profile than steroidal agents, with demonstrated reductions in cardiovascular and renal events in chronic kidney disease and in heart failure, and they position aldosterone synthase inhibitors as a complementary upstream approach with promising early results in resistant hypertension and chronic kidney disease. Combination strategies remain investigational, with ongoing trials in non-diabetic chronic kidney disease.

The third theme is immune-mediated glomerular disease, and here the headline is a randomised trial in Kidney International. Yap and colleagues ran a prospective Asian multicentre trial randomising 130 patients with biopsy-proven class three or four lupus nephritis, with or without class five, to glucocorticoids plus either tacrolimus or mycophenolate as continuous induction-maintenance therapy for 96 weeks [6]. At 96 weeks, sustained renal response was achieved in roughly 59 percent of the tacrolimus group and roughly 69 percent of the mycophenolate group — a difference that was not statistically significant — and complete remission rates were likewise comparable. Overall adverse event rates were identical at 80 percent in both arms, but the profiles differed: acute kidney injury and tremor were more frequent with tacrolimus, leucopenia more frequent with mycophenolate, and treatment-related serious adverse events and serious infections were significantly more frequent in the mycophenolate arm, where all three deaths occurred. The trial supports tacrolimus plus glucocorticoid as a comparably effective alternative with a different safety trade-off, though with 65 patients per arm it is not powered to exclude a modest efficacy difference. That trial lands against a broader perspective from the Immunonephrology Working Group of the European Renal Association, published in Nephrology Dialysis Transplantation, which catalogues the unmet needs in adult lupus nephritis [7]: modest complete remission rates, ongoing glucocorticoid toxicity despite the shift to early triple therapy, uncertainty about treatment duration and safe tapering, high flare rates after withdrawal, the potential role of repeat biopsy, poor adherence being misread as refractory disease, and newer agents remaining inaccessible on cost grounds in many health systems. Kidney International also published a review from Boyer and colleagues on long-term outcomes in childhood idiopathic nephrotic syndrome [8]. Steroid responsiveness remains the strongest prognostic marker; up to a third of children with initial steroid resistance have a monogenic cause. About half of steroid-sensitive patients have frequent relapses or steroid dependence, and around a quarter relapse at least once in adulthood, which challenges the older assumption that most patients outgrow the disease by puberty. Kidney failure and death remain uncommon in steroid-sensitive disease, while the risk of kidney failure is three- to fourfold higher in monogenic or multidrug-resistant steroid-resistant disease.

Two final papers address risk stratification in transplantation and in rare disease. In Kidney International Reports, Bertrand and colleagues retrospectively studied 50 kidney transplant recipients with a first episode of BK polyomavirus DNAemia, measuring virus-specific cellular immunity by interferon-gamma ELISPOT shortly after the first positive plasma test [9]. About three quarters of patients cleared the virus, and stronger responses against structural viral antigens were independently associated with faster clearance, less biopsy-proven BK nephropathy, and a reduced need for major immunosuppression reduction; responses to regulatory antigens were weaker and less consistent. The authors describe their findings as hypothesis-generating and requiring prospective multicentre validation, which is the right framing for 50 patients at a single centre. And in Kidney International, Soncin and colleagues reported from the French DAILY-LUMA cohort of 76 patients with primary hyperoxaluria type 1 treated with lumasiran, including 54 children and 24 patients on dialysis [10]. Just under three quarters met the composite oxalate response criterion at three months. Genotype, classified by vitamin B6 responsiveness, was not significantly associated with response, though there was a non-significant trend toward lesser response in pyridoxine-sensitive forms. The only significant determinants were age at diagnosis and age at initiation, with the best responses in paediatric patients. The authors suggest continuing pyridoxine in sensitive patients even after starting lumasiran, and emphasise systematic reassessment after initiation.

If you only have time for one paper this week, make it the Veterans comparative effectiveness study in the Clinical Journal of the American Society of Nephrology [4]. It is the largest head-to-head look yet at GLP-1 receptor agonists versus SGLT2 inhibitors in older patients with advanced chronic kidney disease, and it reopens the question of whether these agents are interchangeable for kidney protection in exactly the population trials have most often underrepresented.

Here is what this week's evidence adds up to in Nephrology. First, physical function is emerging as a measurable prognostic axis in chronic kidney disease, with cohort data linking lower performance to death and heart failure but not to kidney failure, and a consensus panel now endorsing routine screening — though the evidence that intervention reverses frailty remains thin. Second, in older patients with stage 3 to 4 chronic kidney disease, observational data suggest broadly similar overall outcomes between the two major cardiorenal drug classes, with the kidney-specific signals favouring SGLT2 inhibitors; randomised confirmation in this population is still absent. Third, in class three and four lupus nephritis, a 96-week randomised trial found tacrolimus with glucocorticoid neither better nor worse than mycophenolate for efficacy, with fewer treatment-related serious adverse events, giving clinicians a genuine choice framed around toxicity rather than potency. Fourth, incremental haemodialysis appears non-inferior on hard outcomes and better for residual function and access, but the trial evidence remains insufficient for routine adoption. And finally, both the BK immune-monitoring and lumasiran cohorts point toward stratified management, with age and immune competence rather than genotype driving response — early findings that need prospective validation.

That's your roundup for This Week in Nephrology. The full transcript and references are available on the episode page in your AudioScholar library. This is an AI-curated summary — for clinical decisions, always consult primary sources and current guidelines. See you next week.

If this weekly briefing is useful, follow the show in your podcast app so new episodes arrive automatically. And if it saves you time, a quick rating in your podcast app helps other physicians find the show.

This is an automated summary generated by artificial intelligence, which can make mistakes. Always review the original source materials.